Please provide your email address to receive an email when new articles are posted on . Exposure to a contaminated nearly doubles a patient’s risk for hospital-onset C. difficile infection. This ...

Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile ...

Finch Therapeutics’ lead microbiome drug beat the standard of care at banishing recurrent Clostridium difficile infections in a phase 2 study, laying the groundwork for a second pivotal trial and ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

Mass General Brigham researchers at two hospitals found the metabolic strategies C. difficile uses to rapidly colonize the gut and identified ways to combat the disease, the Somerville, Mass.-based ...

(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile ...

C. diff infection can cause diarrhea. While it may lead your poop to change color, there are no specific colors that are definitive evidence of having C. diff. According to the Centers for Disease ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

We conducted a phase 3, double-blind, randomized, placebo-controlled trial in which patients who had had three or more episodes of C. difficile infection (inclusive of the qualifying acute episode) ...